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Type of Transplant Operation and Role of Screening
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Lung transplantation has become an accepted treatment modality for patients withadvanced lung disease. Despite two decades of experience, limited long-term survival,
caused predominantly by the development of chronic allograft rejection and infection,
remains the main shortcoming of lung transplantation. However, recent reports from large
transplant centers and the International Heart and Lung Transplant Registry reveal
improving survival in lung transplant recipients.1 Data also show a progressive increase in
the mean age of lung transplant recipients with chronic obstructive pulmonary disease
(COPD) and pulmonary fibrosis as the two main indications of lung transplantation. All
of these trends are expected to result in a higher rate of medical complications in
transplant recipients, particularly the development of malignancy.
Malignancy has long been observed as a complication of chronic immunosuppres-
sive therapy in organ transplant recipients. Dysregulation of antitumor immune surveil-
lance, pretransplant environmental exposures such as tobacco smoke and sunlight, and a
variety of viral infections are the main underlying mechanisms contributing to the
development of malignancy. The cumulative risk of developing one or more malignancy,
excluding nonmelanoma skin cancer, in transplant recipients with a functional graft is
nearly 30% after 20 years.2 Skin cancer and lymphoproliferative disorders are the most
frequent types of posttransplant malignancy, irrespective of the transplanted organ type.
However, a wide variety of cancers may develop with specific differences existing based
on type of transplant, characteristics of the patient population, and risk factors. In this
context, bronchogenic carcinoma is pertinent in recipients of lung transplantation.
In the general population, bronchogenic carcinoma is the leading cause of cancer-
related mortality both in men and women. Initial reports, mainly from renal transplant
recipients, have not revealed a significantly higher incidence of bronchogenic carcinoma
compared with the general population. However, more recent studies, and particularly
studies in thoracic organ transplant recipients show a drastically higher incidence in this
patient cohort.3 Indeed, Roithmaier et al.3 recently reported a 9.3 fold increased risk of
developing lung cancer in heart and/or lung transplant recipients compared with the
general population. When skin cancer was excluded, lung cancer was the third most
common malignancy in these patients, following lymphoproliferative disorders and head
and neck cancer.
In this issue of the journal, Minai et al.4 report the largest single center series of
patients who developed bronchogenic carcinoma after lung transplantation. Their findings
were not dissimilar from previous literature. In a cohort of 520 patients, 12 (2.3%)
patients, all of whom were former smokers, developed 13 bronchogenic carcinomas. Most
were of non-small cell histology. Eleven of the 12 patients had COPD and 1 had
pulmonary fibrosis. Eleven of the 12 patients developed bronchogenic carcinoma in their
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native lungs. The prevalence of bronchogenic carcinoma was
higher at 3.84% in patients receiving single lung transplan-
tation and even higher at 5.15% among COPD patients who
received single lung transplantation. Most patients were not
amenable to curative surgical resection resulting in very poor
outcomes within a year of diagnosis. Further review of
literature by the authors led to the identification of 47 other
patients who were diagnosed with bronchogenic carcinoma
after transplantation and revealed similar demographic find-
ings and outcomes.
This article and previous literature on this topic bring
up two important questions. First, should single lung trans-
plantation be abandoned in patients with COPD and possibly
pulmonary fibrosis because of the significantly increased risk
of bronchogenic carcinoma in these patients? Similar to data
presented by Minai et al., other reports on bronchogenic
carcinoma after lung transplantation revealed a much higher
prevalence in single lung recipients. A study specifically
designed to look at risk factors showed that primary lung
cancer occurred in 6.9% of single-lung recipients versus in
none of bilateral lung recipients.5 In multivariate analysis,
single lung transplantation conferred a relative risk of 5.3 for
the development of lung cancer. Given this much higher than
expected incidence and risk of lung cancer following single
lung transplantation, with its attendant poor prognosis, a
question that naturally follows, but cannot be easily an-
swered, is whether single lung transplantation should be
abandoned in patients at risk for posttransplant lung cancer,
particularly those with smoking exposure and COPD. This
question certainly poses a significant ethical dilemma, in
which the benefit of bilateral lung transplantation in decreas-
ing the risk of lung cancer with potential improvement in
long-term outcomes will have to be balanced against the
benefits of single lung transplantation to patients with fatal
lung disease, allowing maximal resource utilization and pro-
longation of the lives of twice as many patients.
The second question is the role of radiologic screening
at regular intervals for candidates and recipients of lung
transplantation. Screening by plain chest radiography is
clearly inadequate in this patient population whose cancers
are missed on prior radiographs approximately 50% of the
time.6 Chest computed tomography (CT) represents a more
sensitive, albeit imperfect detection tool with less than 15%
chance of missing lesions. CT screening for lung cancer in
other populations at risk remains controversial and is cur-
rently not recommended.7 In patients with advanced lung
disease being considered for lung transplantation and who are
at higher risk for lung cancer (former smokers with COPD
and pulmonary fibrosis), it is unlikely that survival due to
lung cancer detection will be altered by the screening process,
particularly since most patients will not be amenable to
curative resection. However, since lung transplantation is an
incredibly expensive treatment modality available for only a
small subset of patients, and the fact that transplantation of
patients with preexisting lung cancer universally results in
very poor outcomes, adding to the cost of pretransplant
testing the expense of annual chest CT may be a small price
to pay. With such a strategy, patients with malignancy can be
excluded from transplantation, avoiding both the high cost
and poor outcomes in this group of patients, and also allow-
ing other patients to undergo transplantation. Posttransplant
screening is perhaps more controversial, sparking the ques-
tion whether outcomes of lung cancer can be improved by
early detection in the immunosuppressed host. As a screen-
ing tool, the cost effectiveness of chest CT is certainly a
major consideration, but less so in transplant patients who
have already been committed to a very expensive treatment
modality.
In summary, bronchogenic cancer has become a signif-
icantly frequent and fatal complication in lung transplant
recipients, predominantly affecting former smokers with
COPD and pulmonary fibrosis who receive single lung trans-
plantation. Our challenges are to resolve how best to detect
lung cancer before and after lung transplantation, determine
the most appropriate transplant procedure for patients at
highest risk and understand the mechanisms by which lung
cancer develops during chronic immunosuppressive therapy.
All of these challenges, if overcome, may lead to a significant
decrease in lung cancer-related mortality in transplant recip-
ients.
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